Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Idun licenses Bcl-2 gene to Selective Genetics

Feb. 28, 2001

Hemosol seeks U.K. approval of Hemolink

Feb. 27, 2001

Takeda will develop a compound for diabetic neuropathy originating at Welfide

Feb. 27, 2001

Bio-Technology General to acquire Myelos

Feb. 27, 2001

Japanese research group identifies new VEGF receptor antagonists

Feb. 26, 2001

Kirin accelerates development of NESP in Asia

Feb. 26, 2001

CuraGen and Bayer cleared to proceed with landmark genomic agreements

Feb. 23, 2001

Adipose tissue hormone reduces body weight by increasing FFA oxidation

Feb. 23, 2001

Phase I/II program for NBI-6024 expanded; pivotal phase IIb trial to commence later this year

Feb. 23, 2001

FDA accepts AHP's PMA for unique bone growth protein

Feb. 23, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...